Harnessing the Immune System Against Cancer by Targeting CD25

Video Mar 16, 2021 | Taken from CRUK, YouTube

The shared CD25 activation mechanism on regulatory and effector T cells has been a big challenge when designing immunotherapy drugs. Cancer Research UK scientists from University College London in collaboration with Roche, have developed a new antibody that can target CD25 specifically on regulatory T cells while leaving effector T cells intact. Watch this antibody in action in this short animation.

Read the Nature paper on this area of research here.

Recommended Videos

The Next Generation of Vaccines and Antiviral Drugs

Video

Antiviral medicines and vaccines are both critical tools in our therapeutic arsenal for combating viral outbreaks. Discover more about vaccines and antivirals in this video from Scripps Research.

WATCH NOW

Introduction to ICP-MS – Part II

Video

In part two of their ICP-MS Teach Me in 10, Abe Gutierrez and Ed McCurdy help to answer the question: Why do we need triple quadrupole ICP-MS?

WATCH NOW

Cubis® II Compliance

Video

For customers requiring Pharmaceutical and GxP compliance, the Cubis®️ II platform is the only laboratory balance on the market today that offers fully customizable hardware, software and connectivity.

WATCH NOW

Like what you just watched? You can find similar content on the communities below.

Biopharma Cancer Research Drug Discovery Immunology & Microbiology

To personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free